Comparison of Mission Statements & Mission Accomplished - Bicon & Shanta Biotech
Transcript of Comparison of Mission Statements & Mission Accomplished - Bicon & Shanta Biotech
COMPARISON OF MISSION STATEMENTS & MISSION ACCOMPLISHED
A Presentation By
SAIFUDHEEN P
Comparison
To what extend Mission Statement justifies the performance?
Mission Statement – A driving force!
Relatedness of Core values with Achievements
BIOCON SHANTHA BIOTECHNICS LTD
MISSION STATEMENT
‘To be an integrated biotechnology enterprise of global distinction.’
‘To develop international Standards, produce and market cost effective human health care products that conform to international quality of high order.’
BIOCON SHANTHA BIOTECHNICS LTD
BIOCONTarget Definitions
Essential to this mission is excellence in:
Intellectual asset creation through discovery, research and development
State-of-the-art manufacturing capabilities Internationally benchmarked quality and
regulatory systems New medical insight through disease specific
clinical research Customer relationship through outstanding
products and services
Continue…
Human resource development through training, mentoring and empowering
Management of research and business partnerships
“To be an integrated biotechnology enterprise of global distinction.”
HISTORY
November 29, 1978
Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated biopharmaceutical enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs
1978
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw
1979
Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
1989
Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International
Biocon is the first Indian biotech company to receive US funding for proprietary technologies
1990
Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level
1993
Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany
1994
Biocon establishes Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector
1996
The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion
1997
Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
1998
Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity
2000
Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
2001
Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering moleculeBiocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent
2002
Clinigene's clinical laboratory is the first in India to receive CAP accreditation
2003
Biocon is the first company worldwide to develop human insulin on a Pichia expression system
2004
Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.
2005
Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East.
2006
Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park
Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.
Biocon launches India's first anti-cancer drug BIOMAb EGFR™.
2007
Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
2008
Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million
And Now…
Biocon is ranked the world’s top 20 biotechnology company by Med Ad News.
Biocon is the 7th largest biotech employer in the world by Med Ad News.
Vision Statement –‘To be an integrated health care company valued for its commitment to ethics, quality and stakeholders.’Mission Statement -‘To develop international Standards, produce and market cost effective human health care products that conform to international quality of high order.’
SHANTHA BIOTECHNICS LTD
Target Definition
Guided by this inspiring credo of Vision & Mission, we hope to reach many more milestones in our quest to improve the quality of human life and the environment.
A pioneer in the field of biotechnology, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. We are committed to breaking new ground in modern biotechnology to address critical healthcare needs of the developing world.
Target Definition
To make cutting edge technologies available to the common man Shantha is constantly exploring the possibilities of partnerships to facilitate innovations in research and development.
A deep sense of commitment and a tradition of excellence have characterized Shantha’s journey thus far and have placed it in the forefront of exciting scientific ventures. However, there are still bigger oceans to be crossed and farther shores to be reached.
Target Definition
We are committed to developing a range of innovative healthcare products of superior quality, ensuring a healthier future for all of us.
PERFORMANCE
A pioneer in the field of biotechnology, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. We are committed to breaking new ground in modern biotechnology to address critical healthcare needs of the developing world.
SHANVAC- B is the first Indian Hepatitis-B vaccine to be pre-qualified by WHO, Geneva, for supplying to UN agencies globally. Today, Shantha caters to major international markets including Asia-Pacific, Africa, CIS and Latin America in addition to supra nations like UNICEF and PAHO.
As the first Indian company to launch an r-DNA vaccine in 1997, Shantha heralded a new beginning for biotechnology in India. Shantha continues to push boundaries and transcend limitations, bolstered by its research-driven scientific ethos.
Shantha Biotechnics Limited (Shantha) has become a part of the Merieux Alliance group after MA acquired the majority shareholding in the company in November, 2006. Merieux Alliance is a France based global organization having presence in all elements of the healthcare chain: prevention, diagnostics, prognosis, treatment and clinical monitoring. The group’s turnover is over US$1.3 billion and has a workforce of more than 9000 people around the globe.
Shantha has also obtained WHO-Geneva Pre-qualification for its combination vaccine of DPT+ Hepatitis-B vaccine ‘SHANTETRA’, enabling supplies to UN Agencies.
Mission Statements - Again
‘To be an integrated biotechnology enterprise of global distinction’
‘To develop international Standards, produce and market cost effective human health care products that conform to international quality of high order.’
Mission & Performance
More relatedness… In between somwhat they lost…